Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (521-530 of 652) with videos related to

Pageof 66
Sort By:
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Leukemia & Lymphoma|October 15, 2024
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myelomaMeletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, et al.
Blood Advances|December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUXAndrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.
Plos One|August 8, 2013
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)George Pentheroudakis, Vassiliki Kotoula, Anastasia G Eleftheraki, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Blood|February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ studyRobert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentMeletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2025
Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study GroupDespina Fotiou, Sorina Nicoleta Badelita, Eirini Katodritou, et al.
Pageof 66

Showing results (521-530 of 652) with videos related to

Sort By:
Pageof 66
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Leukemia & Lymphoma|October 15, 2024
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myelomaMeletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, et al.
Blood Advances|December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUXAndrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.
Plos One|August 8, 2013
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)George Pentheroudakis, Vassiliki Kotoula, Anastasia G Eleftheraki, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Blood|February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ studyRobert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentMeletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2025
Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study GroupDespina Fotiou, Sorina Nicoleta Badelita, Eirini Katodritou, et al.
Pageof 66